Selective toxicity of nitracrine to hypoxic mammalian cells. by Wilson, W. R. et al.
Br. J. Cancer (1984), 49, 215-223
Selective toxicity of nitracrine to hypoxic mammalian cells
W.R. Wilson', W.A. Denny2, S.J. Twigden2, B.C. Baguley2 & J.C. Probert1
'Oncology Section, Department ofPathology, 2Auckland Division Cancer Society ofNew Zealand Research
Laboratory, University ofAuckland School ofMedicine, Private Bag, Auckland, New Zealand.
Summary Hypoxic cells in solid tumours are resistant to ionizing radiation and may be refractory to
treatment by many chemotherapeutic agents. For these reasons the identification of drugs with selective
toxicity towards hypoxic cells is an important objective in cancer chemotherapy. Nitroimidazoles such as
misonidazole demonstrate such hypoxia-selective toxicity but have very low dose potency. The 1-nitroacridine
derivative l-nitro-9-(dimethylaminopropylamino)acridine (nitracrine) binds reversibly to DNA but also forms
covalent adducts with DNA in vivo. We have found nitracrine to be selectively toxic to the Chinese hamster
ovary cell line AA8 under hypoxic conditions in culture, with a potency approximately 100,000 times higher
than that ofmisonidazole. The effect of oxygen is not a simple dose-modifying one in this system, probably in
part because of rapid metabolic inactivation of nitracrine under hypoxic conditions. Viscometric studies with
the mini col E1 plasmid PML-21 confirmed that nitracrine binds to DNA by intercalation, and provided an
unwinding angle of 160 (relative to 260 for ethidium). It is proposed that the cytotoxicity of nitracrine under
hypoxia is due to reductive metabolism to form an alkylating species, but that intercalation of the
chromophore may enhance reactivity towards DNA and hence contribute to the marked enhancement of
potency with respect to simple nitroheteroaromatic drugs.
Hypoxic cells in solid tumours represent an
important problem in radiotherapy because of their
resistance to ionizing radiation. These same cells
are likely to be refractory to many chemothera-
peutic agents since clonogenic cells in regions of
hypoxia arising from limited oxygen diffusion
(Thomlinson & Gray, 1955) are probably largely
non-cycling (Tannock, 1968; Hirst & Denekamp,
1979) and may be protected further by poor
diffusion of drugs from the vasculature (Ozols et
al., 1979; Levin et al., 1980; Tannock, 1982). In
addition, some widely used antitumour agents have
reduced activity under hypoxic conditions in cell
culture (Tannock & Guttman, 1981; Teicher et al.,
1981). For these reasons the need for effective
therapeutic strategies for eliminating hypoxic
tumour cells is now widely recognized.
In the course of developing radiosensitizing drugs
with selectivity for hypoxic cells, it was discovered
that electron-afrinic nitroimidazoles not only
-sensitize hypoxic cells to ionizing radiation, but are
themselves selectively toxic to these cells (Hall &
Roizin-Towle, 1975; Moore et al., 1976). The
selective hypoxic cytotoxicity of agents like misoni-
dazole (MISO) can be demonstrated readily in
culture, and under favourable conditions can also
be detected in vivo (Rauth et al., 1980). However,
cytotoxicity is observed only in the millimolar
concentration range, and the nitroimidazoles appear
to lack the potency required to be useful clinically
as chemotherapeutic agents for hypoxic tumour
cells.
We are currently investigating a strategy with
potential for enhancing the cytotoxic potency of
nitroheterocyclic compounds: since DNA is the
probable target for the reductively activated
metabolite(s) of these drugs (Palcic & Skarsgard,
1978; Varghese & Whitmore, 1980) we are utilizing
chromophores capable of physical binding to DNA
as heteroaromatic nuclei in place of single-ring
systems like imidazole or furan.
In examining DNA-binding chromophores which
could act as carriers for electron-affinic nitro
groups, we noted that the antitumour drug 1-nitro-
9-(dimethylaminopropylamino)-acridine (Ledakrin,
generic name nitracrine; structure Figure 1)
possesses some features of interest (for reviews see
Konopa et al., 1976; Gniazdowski et al., 1979;
Denny et al., 1983). Nitracrine, which was first
synthesized by Ledochowski & Stefanska (1966),
bears a readily reduced (Chodkowski & Kiwak,
1973) nitro group on the acridine nucleus and binds
reversibly to DNA in vitro with high affinity
(Filipski et al., 1975, 1977). Nitracrine has been
shown to have antitumour activity against sarcoma
180 (Radzikowski et al., 1967, 1969), NK
lymphocytic leukaemia, Ehrlich ascites tumour
(Radzikowski et al., 1967), a subline of the Yoshida
sarcoma resistant to alkylating agents
(Kwasniewska-Rokicinska & Winkler, 1969), all in
mice, and against the Walker 256 carcinoma in rats
(Radzikowski et al., 1967). This drug has been used
clinically in Poland for the treatment of mammary,
ovarian, lung and colon carcinomas (Gniazdowski
et al., 1979).
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Figure 1 Structures of acridine derivatives
investigated. I: 1-nitro-9-(dimethylaminopropyl-
amino)acridine (nitracrine). II: 4'-(9-acridinyl-
amino)methanesulphon-m-anisidide (amsacrine).
In the present study we report the cytotoxic
activity of nitracrine against hypoxic and euoxic
mammalian cells in culture as a possible
representative of a class of electron- and DNA-
affinic nitroheterocyclic drugs. For purposes of
comparison we have also evaluated the cytotoxicity
of misonidazole, and the antileukaemia drug
amsacrine (Figure 1), the latter as a representative
of the other main class of antitumour acridines
(Denny et al., 1983).
Materials and methods
Drugs
MISO was obtained as a gift from Roche
Laboratories through the courtesy of Dr K.M.
Taylor, Dept of Pharmacology, University of
Auckland. Nitracrine was synthesized in this
laboratory from 1-nitro-9-chloroacridine and N,N-
dimethylaminopropylamine by phenol catalysis
using standard methods (Albert, 1966). Crystal-
lization from methanol/ethyl acetate/dry HCl gave
orange microcrystals of the dihydrochloride, m.p.
222-2250C. (Literature m.p. 223-224°C,
Ledochowski & Stefanska, 1966). Amsacrine was
synthesized as reported previously (Cain et al.,
1975) and converted to the isethionate salt.
Ethidium bromide and 9-aminoacridine hydro-
chloride were purchased from Sigma Chemical Co.,
U.S.A. Sterile stock solutions were prepared by
dissolving drugs in ethanol:H20 (1:1, v/v)
immediately before use and diluting into culture
medium to give a final concentration of ethanol not
exceeding 0.1%.
Cells
AA8 cells (Thompson et al., 1980), a subline of
CHO, were obtained from Dr L.H. Thompson,
Lawrence Livermore Laboratory, and maintained in
logarithmic-phase growth as subconfluent mono-
layers by trypsinization and subculture to 104 cells
per 25cm2 T-flask twice weekly. The growth
medium was ALPHA MEM containing 10% v/v
heat-inactivated (56°, 40min) foetal calf serum
(FCS) without antibiotics. These cells were myco-
plasma-free as judged by cytochemical staining
(Chen, 1977). Larger stocks of cells were prepared
by growth in this same medium (doubling time 13-
14h) in spinner flasks flushed with 5% CO2 in air.
Aerobic and hypoxic cytotoxicity
Spinner cultures were grown to plateau phase
(- 6h after cessation of net growth at 1.1 to
1.2 x 106 cellsml-1) and then exposed to drugs
under hypoxic or euoxic conditions using a modi-
fication of the system described by Whillans &
Rauth (1980). Drug solutions at 1.25 times the
required final concentration were prepared in 8ml
of plating medium (ALPHA MEM containing 5%
heat-inactivated FCS, 100Uml-P penicillin, and
100 igml-1 streptomycin) and incubated with
stirring in universal bottles containing teflon-coated
spin bars in a waterbath at 37°C. The lids of these
bottles were modified to provide gas inlet (18 gauge
needle) and exit (1.2mm ID latex tubing) ports
allowing continuous flushing with humidified 5%
CO2 in either air or nitrogen (analysed oxygen
content < 10 parts per million) at a rate of
200mlmin-1. At the same time, cell suspensions at
5 x106 cellsml- in plating medium, obtained by
concentrating plateau phase spinner cultures by
centrifugation, were also gassed with 5% CO2 in air
or nitrogen. After equilibration with these gases for
45min drug exposure was initiated by transferring
2ml of cell suspension into each drug solution,
using a syringe and spinal needle which was flushed
with nitrogen before loading the hypoxic cell
suspension. Samples (0.06 or 0.6ml) were
withdrawn at intervals via the gas exit port using a
spinal needle without interrupting gas flow, and
immediately diluted into 5ml of plating medium.
Cells were centrifuged and resuspended once in
plating medium, the cell density determined
with a Coulter counter, and 102-105 cells plated in
60mm diameter Falcon petri dishes to give a final
volume of 5ml. Adequacy of drug washout was
tested by plating 102 untreated cells in additional
dishes containing 104 or 105 heavily treated cells
where few or no treatment survivors were expected.
In all such tests plating efficiencies and colony sizes
were in the normal control range. Colony formation
was assessed after incubating for 8 days by stainingHYPOXIA-SELECTIVE TOXICITY OF NITRACRINE
with 0.5% methylene blue in ethanol and counting
colonies containing > 100 cells.
DNA binding
The association constant (K) for binding of
nitracrine to DNA was determined using a
previously described (Baguley et al., 1981) fluori-
metric ethidium displacement technique, which has
been shown to give reliable determination of
acridine-DNA binding affinity (Wilson et al.,
1981b). In brief, small aliquots of a concentrated
solution of nitracrine were added to 0.01 SHE
buffer (9.4mM NaCl, 2mM HEPES, 10MM Na2
EDTA, adjusted to pH 7.0) containing ethidium
bromide (1.26 uM) and native calf thymus DNA
(type V, Sigma Chemical Co.) at 1 uM DNA
phosphate. The decrease in fluorescence intensity
induced by acridines is due to displacement of
ethidium and to fluorescence quenching of the
ethidium:DNA complex (Baguley et al., 1981). The
contribution of the latter process was determined in
a separate assay using a low ethidium:DNA ratio
(Baguley et al., 1981). Association constants were
calculated from the fluorimetry data using a
neighbouring site exclusion model (McGhee & Von
Hippel, 1974), assuming a binding site size of 2
base pairs (see Results).
Viscometric titrations ofsupercoiled DNA
The extent of unwinding of the DNA double helix
accompanying intercalation of drugs was
determined by measuring the reduced viscosity of
solutions of covalently closed circular DNA. The
method followed the procedure described by Cain
et al. (1978), except that the DNA used was a mini
col E1 plasmid, PML-21 (Herschfield et al., 1976),
which was isolated by sedimentation to equilibrium
in ethidium bromide/CsCl gradients. Using a plastic
catheter small aliquots of a concentrated drug
solution were added to a solution containing 55,g
DNA in 1.1 ml of 0.01 SHE buffer in a capillary
viscometer at 25.0+0.10. The helix unwinding angle
was calculated as 260 xre/rd, where re and rd are
the bound drug to DNA phosphate molar ratios at
the equivalence point (maximum in the viscometric
titration) for ethidium bromide and the test drug
respectively. Binding ratios were calculated from
input drug to DNA phosphate ratios (D/P) using
the association constants determined above.
Results
Incubation of stirred suspensions of plateau phase
AA8 cells with MISO demonstrated the selective
cytotoxicity -of this compound under hypoxic
conditions (Figure 2). The MISO survival curve for
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Figure 2 Plating efficiency ofplateau phase AA8 cells
(106ml-1) exposed to misonidazole at 3.75mM (A,L
A) or amsacrine at 2MM (El, *) under aerobic (open
symbols) or hypoxic (filled symbols) conditions.
Controls (0, 0) were incubated under identical
conditions in the absence of drugs. In this and
subsequent figures standard errors for colony counting
statistics are less than the size of the plotted points
unless shown.
AA8 under hypoxia was similar to that described
for other CHO sublines (Moore et al., 1976; Taylor
& Rauth, 1980) with a threshold prior to the onset
of exponential killing. In contrast, no such
selectivity was observed with the antitumour
acridine derivative amsacrine (Figure 2) in
agreement with previous studies using log-phase
V79-171b cells in microcarrier culture (Wilson et
al., 1981a).
Nitracrine displayed selective toxicity towards
hypoxic AA8 cells, with a pronounced differential
between killing of aerobic and hypoxic cells at a
concentration of 0.1 pM (Figure 3). At lower drug
concentrations appreciable killing of hypoxic cells
was observed (Figure 4) in the absence of detectable
toxicity at these concentrations and exposure times
in oxygenated cultures (data not shown). Oxygen
clearly does not act in a strictly dose-modifying
manner in this system, the shapes of survival curves
differing under hypoxia and euoxia with a less
conspicuous shoulder and a marked decrease in the
rate of kill at late times under hypoxic conditions
(Figures 3 and 4). Nonetheless, at early times
(<2h) the cytotoxic potency of nitracrine is
enhanced by at least a factor of 5.in the absence of
oxygen. (Compare 0.1 or 0.04uM nitracrine under
hypoxia with 0.5 or 0.2MM respectively under
aerobic conditions, Figures 3 and 4.)
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Figure 3 Plating efficiency of plateau phase AA8 cells
(106ml-1) exposed to nitracrine under aerobic (open
symbols) or hypoxic (filled symbols) conditions at
concentrations of 0.1 (El, O, *, *), 0.2 (A, V) or
0.5 (D>) pM. Controls (0, 0) were incubated under
identical conditions in the absence of drugs. Different
symbols for the same drug concentration refer to
independent experiments.
Precise comparison of the potencies of MISO and
nitracrine is not possible since the kinetics of killing
by each is very different. However, it is evident that
nitracrine is in the order of 105 times more potent
than MISO. Thus, while MISO at 3.75mM reduced
the surviving fraction by a factor of ten in 2.5h
(Figure 2), a comparable level of cell kill was
obtained at this time by nitracrine at only 0.04 M
(Figure 4). It is noteworthy that, unlike MISO,
there was little delay in the onset of cell killing by
nitracrine.
The marked deviation from exponential cell
killing by nitracrine under hypoxia is suggestive of
a rapid loss of drug activity in culture. Preliminary
studies showed nitracrine to be relatively stable in
aerobic ALPHA MEM containing 10% FCS,
preincubation of the drug under these conditions
for 24h causing no significant decrease in its
cytotoxic potency as assessed by measuring
subsequent growth inhibition of AA8 cells in
exponential-phase cultures (data not shown). To
determine whether nitracrine activity is rapidly lost
under hypoxia at high cell density, the drug
(0.1 MM) was incubated in growth medium while
gassing with 5% CO2 in nitrogen in the presence or
absence of plateau phase AA8 cells for 45min
Time (h)
Figure 4 Plating efflciency of plateau phase AA8 cells
(106ml-1) exposed to nitracrine under hypoxic
conditions at 0.02 (A), 0.04 (7), or 0.07 (U) pM, or
in the absence of drug (0). The dashed curve
represents plating efficiency in the presence of
nitracrine at 0.1 pM under hypoxia, redrawn from
Figure 3.
before introduction of non drug-treated cells under
hypoxic conditions. Upon introduction of an equal
number of fresh cells to plateau phase cultures the
plating efficiency increased to - 50% as expected,
and subsequently declined much more slowly than
when the drug was preincubated under hypoxia in
the absence of cells (Figure 5). This experiment thus
clearly demonstrated a rapid loss of nitracrine
cytotoxic activity. The residual cytotoxic activity in
cultures after hypoxic incubation was not observed
when the gas phase was changed to 5% CO2 in air
5min before the introduction of fresh cells (Figure
5). Thus no indication of an accumulation of a
stable proximal cytotoxic metabolite was seen. A
further experiment in which nitracrine at 0.07YM
was preincubated with plateau phase cells at 106
cellsml-l under hypoxia for 3h demonstrated
complete loss of cytotoxic activity upon
introduction of fresh hypoxic cells at this time. A
similar, although less marked, loss of cytotoxic
activity was observed upon incubation of aerobic
plateau phase cultures with nitracrine at 0.5,M for
3h, the time for reduction of surviving fraction by
l/e being increased from 0.25 to 0.47h on the
exponential part of the survival curve by
preincubation in the presence ofcells (Figure 6).
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Figure 5 Residual cytotoxic activity after pre-
incubation of nitracrine (0.1 pM) under hypoxia in the
presence and absence of AA8 cells. Plateau phase
cultures (10ml) at 106 cellsml-l were treated with
nitracrine under hypoxia for 45min (0) or under
hypoxia for 40min with transfer to a gas phase of 5%
C02/air (A) 5min before addition (arrow) of an equal
number of non-drug treated hypoxic cells in 2ml to
give a final (nominal) drug concentration of 0.083MM.
Incubation was then continued under hypoxic (-) or
aerobic (A) conditions. Nitracrine (0.1MM) was also
incubated in plating medium without cells for 45min
under hypoxia (M) before addition (arrow) of hypoxic
cells to a density of 106ml-1 giving a final (nominal)
drug concentration of 0.083pM. The control (0) was
incubated at 106 cellsml-1 under hypoxia without
drug treatment.
In order to examine the mode of interaction of
nitracrine with DNA, its effect on the supercoiling
of PML-21, a covalently closed circular mini col E1
plasmid, was determined. Removal of supercoiling
(raising of reduced viscosity) followed by induction
of supercoils of the reversed sense provided
evidence for intercalation (Figure 7). Input drug to
DNA phosphate (D/P) ratios at the equivalence
point were corrected for unbound drug using
association constants determined by the ethidium
displacement method (Table I). The resulting
binding ratios (r) at the equivalence points were
used to calculate the helix unwinding angles (Table
I). Intercalation of nitracrine induced a 160 helix
unwinding relative to a value of 26° for ethidium
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Figure 6 Residual cytotoxic activity after pre-
incubation of nitracrine (0.5MM) under aerobic
conditions in the presence and absence ofAA8 cells. A
plateau phase culture (10ml) at 106 cellsml-1 was
treated with nitracrine under aerobic conditions for 3h
(O) before addition (arrow) of an equal number of
untreated euoxic cells in 2ml to give a final (nominal)
drug concentration of 0.417MM. Nitracrine (0.5pM)
was also incubated in plating medium without cells for
3h before addition of untreated euoxic cells to a final
density of 106 cellsml-1, giving a final (nominal) drug
concentration of 0.417MM (U). The control (0) was
incubated at 106 cellsml-l under aerobic conditions
without drug treatment.
(Wang, 1974). A similar value of 15° was obtained
with 9-aminoacridine suggesting that the 1-nitro
group and charged dialkylaminoalkylamino
sidechain in the 9-position of the acridine ring do
not markedly influence intercalation geometry.
Amsacrine, with its bulky substituted anilino ring in
the 9-position, provided an unwinding angle of 210
in good agreement with the previously reported
value of 20.50 (Waring, 1976).
The above calculations assume a site size of 2
base pairs (i.e., neighbouring site exclusion) for
ethidium and for each acridine. Published spectro-
photometric studies (Filipski et al., 1975) of
nitracrine-DNA binding have not been analysed in
a manner providing a site size which can be used in
B.J.C.-F
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Figure 7 Effects of nitracrine (0), 9-aminoacridine
(0), amsacrine (A), and ethidium bromide (0) on the
reduced viscosity (ordinate) of covalently closed
circular duplex DNA from the E. coli plasmid PML-
21. The molar ratio of drug to DNA phosphate (D/P)
is shown on the abscissa.
Table I Physical binding to native DNA in 0.01 SHE
buffer
Equivalence point
Unwinding
Ligand K(M-1)a D/pb rc angle
Ethidium 2.1 x 106 0.0440 0.0437 260
Nitracrine 2.3 x 105 0.0765 0.0705 160
9-Aminoacridine 3.9 x 105 0.0815 0.0774 15°
Amsacrine 1.4 x 105 0.0575 0.0533 210
aAssociation constant for binding to calf thymus DNA
determined by the ethidium displacement method. The
values for ethidium, 9-aminoacridine and amsacrine have
been published previously (Wilson et al., 1981b). All data
are corrected for fluorescence quenching of the
ethidium:DNA complex. For nitracrine this correction
decreases the estimate of K by 8%.
bInput drug to DNA phosphate molar ratio at the
equivalence point in the viscometric titration of PML-21
DNA.
cBound drug to DNA phosphate molar ratio at the
equivalence point in the viscometric titration of PML-21
DNA.
the neighbouring site exclusion model of McGee &
Von Hippel (1974), but imply that the nitracrine
site size may be atypically large in comparison with
other aminoacridines. Site sizes of 3 or 4 base pairs
would increase the estimated nitracrine association
constant from 2.3 x 105M-1 to 3.8 x l05 and
7.2x l05M-1 respectively. However, because the
estimated proportion of bound drug decreases with
increasing assumed site size, the estimated
nitracrine unwinding angle increases by only 0.1
and 0.2° for site sizes of 3 and 4 base pairs
respectively.
Discussion
In choosing to evaluate the cytotoxicity of
nitracrine under hypoxic and euoxic conditions we
considered that the presence of a readily reduced
nitro group on a heterocyclic nucleus might confer
hypoxia-selective toxicity through a pathway similar
to that for the nitroimidazoles (Brown, 1982). The
predicted selective toxicity under hypoxia has been
demonstrated (Figures 3 and 4). However, the
properties of nitracrine in this experimental system
differ in three respects from MISO.
1. Little or no threshold is evident prior to the
onset of killing by nitracrine, in clear distinction to
the kinetics of killing observed with MISO (Figure
2). If this shoulder with MISO is due to depletion
of endogenous thiols (Varnes et al., 1980; Taylor et
al., 1982) then such a process may be of lesser
importance with nitracrine. Previous studies have
indicated that reaction of nitracrine with DNA may
be thiol-mediated (Gniazdowski et al., 1975), so
endogenous thiols could potentiate rather than
protect from nitracrine toxicity. In addition, the
low molar concentrations of nitracrine used,
relative to MISO, makes it unlikely that direct
titration of intracellular thiols will be of
significance. Whatever the mechanistic basis for the
observed difference between the two drugs, the
rapid onset of killing by nitracrine may be an
advantageous feature. In particular, if a large
component of radiobiological hypoxia is due to a
fluctuating blood supply (Brown, 1979) then
exploitation of the resulting transient hypoxia will
require agents with this characteristic.
2. After the initial shoulder, a constant first-
order rate of killing by MISO is observed over the
measurable range (Figure 1), while for nitracrine at
low concentrations the rate of cell kill decreases
markedly with time (Figure 4). The latter
phenomenon could, in principle, be due to cell cycle
stage selectivity or some other form of
heterogeneity in responsiveness within the hypoxic
cell population. However, the results illustrated in
Figure 5 indicate a rapid loss of drug activity inHYPOXIA-SELECTIVE TOXICITY OF NITRACRINE 221
hypoxic cultures, suggesting metabolic inactivation
of nitracrine, or its sequestration by non-target
binding sites. The difference between nitracrine and
MISO need not reflect a different absolute rate of
metabolism since the much higher concentration of
MISO used would delay depletion. Loss of
nitracrine is also observed under euoxic conditions
(Figure 6), but as yet no direct comparison of the
rate of metabolism under hypoxia and euoxia has
been made.
3. Nitracrine is -105-fold more potent than
MISO as a hypoxic cell cytotoxic agent. Although
the one-electron reduction potential (E1) of
nitracrine has not been reported, it is obvious that
this compound will represent an anomaly with
respect to the previously described correlation
between E17 and hypoxic cell toxicity for simple
nitroheterocycles (Adams et al., 1980).
The high potency of nitracrine is consistent with
the hypothesis that the capacity of the acridine
chromophore for intercalative binding to DNA
might enhance the reactivity of reduced
intermediates toward alkylation of DNA. It might
be expected that the lack of planarity of the
acridine chromophore in nitracrine, arising from
steric interaction between the 1-NO2 group and 9-
dimethylaminopropylamino side chain (Dauter et
al., 1975), would decrease the propensity for
intercalation. Furthermore, the density of binding
sites in double-stranded DNA appears to be lower
than that for other nitro- or aminoacridines
(Filipski et al., 1975), and nitracrine physically
bound to DNA has less effect on template activity
in vitro than have the isomeric derivatives with the
nitro group in the 2, 3, or 4 position (Pawlak et al.,
1983). Despite this, the action of nitracrine in
releasing and reversing supercoiling in closed
circular DNA, shown by viscometric titration
(Figure 7), provides convincing evidence for an
intercalative binding mode. The unwinding angle of
16° is, in fact, similar ro that of the unsubstituted
parent compound, 9-aminoacridine. These results
confirm a previous report demonstrating
intercalative binding on the basis of changes in
sedimentation properties of circular DNA (Filipski
et al., 1977). The tolerance to substitution in the 1
and 9 positions with respect to intercalative binding
suggests that metabolites of nitracrine, as well as
the parent drug, will be able to bind to DNA by
this mode.
Considerable evidence now suggests that the
aerobic cytotoxicity of nitracrine is due to the
formation of covalent DNA adducts (Konopa et
al., 1983; Pawlak et al., 1983) rather than reversible
physical complexes. The metabolism of nitracrine
appears to be complex, with several competing
routes available (Pawlak & Konopa, 1979).
Reductive metabolism to the 1-hydroxylamine has
been suggested to be responsible for the aerobic
cytotoxicity of nitracrine (Konopa et al., 1976), but
the total covalent binding of labelled nitracrine to
macromolecules in rat liver microsome preparations
has been found to be decreased under hypoxia
(Pawlak & Konopa, 1979). Metabolite(s) giving rise
to protein adducts as observed in the latter study
may differ from those responsible for cytotoxicity,
which may act by inducing interstrand crosslinking
of DNA (Konopa et al., 1983). It should be noted
that this apparent potential for bifunctional
covalent reaction with DNA could provide an
alternative explanation for the high dose potency of
nitracrine relative to the nitroimidazoles, which
appear to cause DNA strand scission (Palcic &
Skarsgard, 1978; Taylor et al., 1982) rather than
interstrand crosslinking. The high potency of nitra-
crine under hypoxia suggests that evaluation of
other chromophores offering both high DNA
binding and high electron affinity is warranted.
Such studies will help to clarify the hypothesized
importance of physical DNA binding in the action
of nitroheterocyclic drugs.
Preliminary results suggest that nitracrine is a
potent radiosensitizer of hypoxic AA8 cells (W.R.
Wilson, unpublished observations). The efficacy of
this agent as a chemosensitizer of hypoxic cells also
warrants investigation.
Despite clinical evidence of antitumour activity
(Gniazdowski et al., 1979) and an absence of
myelosuppressive effects (Bratkowska-Seniow et al.,
1974), nitracrine has attracted little interest outside
Poland. Whether the selective killing of noncycling
hypoxic Chinese hamster cells in culture observed
in the present study will also apply to hypoxic cells
in human tumours remains to be determined.
However, if nitracrine reaches such cells without
excessive metabolic depletion, and if in vivo toxicity
is not prohibitive, then its use in combination with
treatment modalities which are limited by a sparing
of hypoxic cells could provide a highly effective
strategy for the treatment of solid tumours.
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